Skip to Main Content
Table 3

Potential targets to inhibit the activation and proinflammatory effects of innate leukocytes known to be involved in the onset and progression of T1D

PathwayCandidate agents
Inflammasomes OLT1177, inzomelid, IZD334, withaferin-A 
Chemokines CXCL12 antibodies, SB225002, SB656933, reparixin, ladarixin, navarixin, danirixin, AZD5069, AZD8309 
Formation of NETs (NETosis) GSK484 
Enzymes secreted by innate leukocytes  
 NE AAT, silvelestat, AZD9668, BAY-678, BAY 85-8501 
 MPO AZD5904, AZD3421, PF-06282999 
PathwayCandidate agents
Inflammasomes OLT1177, inzomelid, IZD334, withaferin-A 
Chemokines CXCL12 antibodies, SB225002, SB656933, reparixin, ladarixin, navarixin, danirixin, AZD5069, AZD8309 
Formation of NETs (NETosis) GSK484 
Enzymes secreted by innate leukocytes  
 NE AAT, silvelestat, AZD9668, BAY-678, BAY 85-8501 
 MPO AZD5904, AZD3421, PF-06282999 
Close Modal

or Create an Account

Close Modal
Close Modal